Comprehensive Guide: Tumor Endoprosthetic Reconstruction (Proximal Humerus)

1. Introduction & Overview

Tumor endoprosthetic reconstruction of the proximal humerus represents a pinnacle of orthopedic oncology and reconstructive surgery. When primary bone tumors (such as osteosarcoma, chondrosarcoma, or Ewing sarcoma) or metastatic lesions compromise the structural integrity of the proximal humerus, limb-salvage surgery becomes the gold standard.

Unlike radical amputation, which historically was the only option for malignant humeral tumors, endoprosthetic reconstruction allows for the excision of the tumorous bone while preserving the distal limb's function. This procedure involves replacing the resected proximal humerus with a modular metallic implant, typically coupled with soft-tissue attachment mechanisms to restore glenohumeral stability and some degree of motor function.

2. Technical Specifications & Mechanisms

The proximal humeral endoprosthesis is a highly specialized modular system. Modern implants are typically manufactured from titanium alloy (Ti-6Al-4V) for its biocompatibility and osseointegration properties, or cobalt-chrome for high-wear articulating surfaces.

Core Components

The mechanism relies on "press-fit" or cemented fixation into the distal humeral canal. The most critical technical challenge is the restoration of the "rotator cuff sleeve." Without secure reattachment of the remaining musculature (deltoid, supraspinatus, infraspinatus), the prosthesis will suffer from instability, leading to subluxation or dislocation.

3. Clinical Indications & Usage

The decision to proceed with endoprosthetic reconstruction is multidisciplinary, involving orthopedic oncologists, radiologists, and medical oncologists.

Primary Indications

• Malignant Primary Bone Tumors: High-grade osteosarcoma, chondrosarcoma, or Ewing sarcoma localized to the proximal humerus.
• Metastatic Bone Disease: Pathological fractures or impending fractures where the tumor burden is too great for simple internal fixation (e.g., metastatic breast, lung, or renal cell carcinoma).
• Aggressive Benign Tumors: Giant Cell Tumor (GCT) of bone with extensive cortical destruction that cannot be managed with intralesional curettage.

Contraindications

• Neurovascular Involvement: Tumor encasement of the brachial plexus or axillary artery.
• Infection: Active sepsis or overlying soft-tissue infection at the surgical site.
• Systemic Status: Poor performance status or limited life expectancy where the morbidity of the surgery outweighs the functional benefit.

4. Patient Pre-operative Preparation

Preparation is rigorous to ensure oncological margins and functional optimization.

1. Imaging: MRI of the entire humerus to assess intramedullary extent; CT of the chest/abdomen/pelvis for staging.
2. Biopsy: Core needle biopsy is mandatory, performed by the operating surgeon to ensure the biopsy tract can be excised during the definitive procedure.
3. Neoadjuvant Therapy: For high-grade sarcomas, patients typically undergo cycles of chemotherapy prior to surgery to shrink the tumor and treat micrometastatic disease.
4. Vascular Mapping: Angiography or CT-angiography to confirm the anatomical relationship between the tumor and the axillary/brachial vessels.

5. The Procedure: Surgical Intervention

The surgery is performed under general anesthesia, usually in a lateral decubitus or "beach-chair" position.

1. Incision: A deltopectoral approach is standard, providing excellent exposure of the glenohumeral joint and the proximal humeral shaft.
2. Resection: The tumor is resected with a wide margin. The axillary nerve is identified and protected. The rotator cuff tendons are tagged for later reattachment.
3. Reconstruction: The distal humeral canal is prepared using broaches. The modular prosthesis is assembled to match the exact length of the resected bone.
4. Fixation: The stem is inserted into the distal humerus (cemented or uncemented).
5. Soft-Tissue Reconstruction: This is the most crucial step. The deltoid and rotator cuff muscles are sutured to the prosthesis via a Dacron sleeve or specialized collar. This prevents the "drooping shoulder" effect and provides a fulcrum for the arm.
6. Closure: Layered closure with drains to prevent hematoma formation.

6. Post-operative Recovery Protocol

Recovery is staged to protect the soft-tissue repairs.

• Phase I (0–6 Weeks): Immobilization in an abduction pillow or sling. Passive range of motion (ROM) only.
• Phase II (6–12 Weeks): Gentle active-assisted ROM. Focus on scapular stabilization exercises.
• Phase III (3+ Months): Strengthening of the periscapular muscles. Return to activities of daily living (ADL). Lifting restrictions (usually <5 lbs) are often permanent.

7. Risks and Potential Complications

While life-saving and limb-salvaging, the procedure carries significant risks:

8. Alternative Treatments

• Allograft-Prosthetic Composite (APC): Uses a cadaveric bone graft combined with a prosthesis to facilitate biologic bone healing.
• Rotationplasty: Rare for the humerus, but involves rotating the distal limb to act as a functional joint; usually reserved for pediatric patients.
• Amputation (Forequarter): Reserved for cases where the tumor is unresectable due to neurovascular involvement.

9. Frequently Asked Questions (FAQ)

1. How long does a proximal humerus endoprosthesis last?
Survival rates are approximately 80–90% at 5 years and 70% at 10 years. Longevity depends on patient activity level and bone quality.

2. Can I lift heavy objects after surgery?
No. Patients are generally advised to avoid lifting more than 5 pounds with the affected arm to prevent premature loosening of the implant.

3. Will I have normal shoulder motion?
Expectation management is vital. Most patients achieve functional motion (enough for ADLs), but full range of motion (especially overhead) is rarely restored.

4. What happens if the implant gets infected?
Infection is a serious complication. It may require a multi-stage revision: removing the implant, placing an antibiotic-loaded cement spacer, and returning once the infection is cleared to insert a new prosthesis.

5. Is chemotherapy required before surgery?
For malignant sarcomas, yes. Neoadjuvant chemotherapy is the standard of care to maximize long-term survival.

6. Does the "metal" get cold in the winter?
Patients often report a sensation of coldness in the limb, as metallic implants conduct temperature more efficiently than bone.

7. Will I need physical therapy forever?
Long-term home exercise programs are recommended to maintain the strength of the muscles surrounding the implant.

8. Can I play sports after this surgery?
Non-impact sports like swimming or light cycling may be permitted, but contact sports or heavy lifting are strictly contraindicated.

9. How do you reattach the muscles to metal?
We use a combination of Dacron mesh sleeves and orthopedic sutures that pass through holes in the prosthesis collar, allowing the tendons to "heal" against the device.

10. Is this surgery considered "curative"?
It is part of a curative intent plan. The surgery removes the local tumor, while chemotherapy/radiation addresses systemic or microscopic disease.

10. Conclusion

Tumor endoprosthetic reconstruction of the proximal humerus is a sophisticated surgical intervention that balances oncological safety with functional preservation. While the procedure requires a lifetime of vigilance regarding implant integrity and soft-tissue health, it offers a vastly superior quality of life compared to historical alternatives. Success is predicated on precise surgical technique, aggressive soft-tissue reconstruction, and a dedicated post-operative rehabilitation team. Patients should maintain open communication with their orthopedic oncology team to monitor for potential complications and ensure the longest possible lifespan for their reconstruction.